Literature DB >> 12114361

Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion.

Etsuko Tagaya1, Jun Tamaoki, Mitsuko Kondo, Atsushi Nagai.   

Abstract

STUDY
OBJECTIVE: Long-term administration of macrolide antibiotics reduces sputum production in patients with chronic airway diseases, probably by inhibiting airway inflammation. The objective of the present study was to determine the acute effects of a macrolide on airway chloride secretion and sputum production.
METHODS: We first investigated the effect of erythromycin treatment on chloride diffusion potential difference (CPD) across tracheal mucosa in vivo. Next, we conducted a double-blind, parallel-group study examining the effect of 7 days of treatment with clarithromycin (400 mg/d), amoxicillin (1,500 mg/d), or cefaclor (750 mg/d) in patients with chronic bronchitis or bronchiectasis without apparent respiratory infection.
RESULTS: IV administration of erythromycin decreased the CPD of rabbit tracheal mucosa in a dose-dependent manner. Treatment of patients with clarithromycin decreased sputum production, whereas amoxicillin and cefaclor treatment had no effect. The percentage of patients whose sputum decreased > 30% from baseline (responders) was 38% in the clarithromycin group, 7% in the amoxicillin group, and 0% in the cefaclor group. During treatment with clarithromycin, the sputum solid composition increased and chloride concentration decreased in responders, but these changes were not observed in nonresponders.
CONCLUSION: Short-term administration of 14-membered macrolide reduces chronic airway hypersecretion, presumably by inhibiting chloride secretion and the resultant water secretion across the airway mucosa.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12114361     DOI: 10.1378/chest.122.1.213

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  17 in total

1.  Clarithromycin in the Treatment of Legionella pneumophila Pneumonia Associated with Multiorgan Failure in a Previously Healthy Patient.

Authors:  L Gallelli; V Gioffrè; G Vero; A Gallelli; F Roccia; S Naty; G Pelaia; A Capano; A Loiacono; G De Sarro; R Maselli
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 2.  The Role of Macrolides in Chronic Rhinosinusitis (CRSsNP and CRSwNP).

Authors:  Gretchen M Oakley; Richard J Harvey; Valerie J Lund
Journal:  Curr Allergy Asthma Rep       Date:  2017-05       Impact factor: 4.806

Review 3.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

Review 4.  Immunomodulatory effects of macrolide antibiotics in respiratory disease: therapeutic implications for asthma and cystic fibrosis.

Authors:  Sanjiv Sharma; Adam Jaffe; Garth Dixon
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

5.  Effects of six-week clarithromycin therapy in corticosteroid-dependent asthma: A randomized, double-blind, placebo-controlled pilot study.

Authors:  Mark H Gotfried; Rose Jung; Chad R Messick; Israel Rubinstein; Kevin W Garey; Keith A Rodvold; Larry H Danziger
Journal:  Curr Ther Res Clin Exp       Date:  2004-01

6.  Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa.

Authors:  Evangelos J Giamarellos-Bourboulis; Theodoros Adamis; George Laoutaris; Lambros Sabracos; Vassilios Koussoulas; Maria Mouktaroudi; Despina Perrea; Panayotis E Karayannacos; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

Review 7.  Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults.

Authors:  Khin Hnin; Chau Nguyen; Kristin V Carson; David J Evans; Michael Greenstone; Brian J Smith
Journal:  Cochrane Database Syst Rev       Date:  2015-08-13

Review 8.  Macrolide therapy in respiratory viral infections.

Authors:  Jin-Young Min; Yong Ju Jang
Journal:  Mediators Inflamm       Date:  2012-06-06       Impact factor: 4.711

Review 9.  Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics.

Authors:  Helen C Steel; Annette J Theron; Riana Cockeran; Ronald Anderson; Charles Feldman
Journal:  Mediators Inflamm       Date:  2012-06-21       Impact factor: 4.711

Review 10.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.